BioCentury | Aug 15, 2019

Deciphera’s $400M follow-on adds firepower on strength of GIST readout

Outsized investor demand continues unabated for stocks of companies with late stage clinical success stories, as evidenced by Deciphera’s ability to double the size of its follow-on to $400 million with little to no haircut...
BC Extra | Jun 1, 2017
Financial News

Deciphera raises $52M in series C

Deciphera Pharmaceuticals LLC (Waltham, Mass.) raised $52 million in a series C round led by Viking Global Investors, Redmile Group and Sphera Global Healthcare Fund. Existing investor New Leaf Venture Partners also participated. Using its...
BC Week In Review | Mar 10, 2017
Clinical News

DCC-3014: Ph I started

Deciphera began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate once-daily DCC-3014, starting at a 10 mg dose, in 28-day cycles in up to 55 patients. Malignancies include solid tumors, acute myelogenous leukemia...
BC Week In Review | Mar 28, 2016
Clinical News

Deciphera preclinical data

In a mouse model of colorectal cancer, once-daily 10 mg/kg DCC-3014 inhibited infiltrating tumor-associated macrophages. Next month, data will be presented at the American Association for Cancer Research meeting in New Orleans. Next half, Deciphera...
BioCentury | Sep 28, 2015

Deep pockets

With four unpartnered cancer compounds in or entering the clinic, Deciphera Pharmaceuticals LLC decided it was finally time to raise venture money. Last week's $75 million series B round from a syndicate led by New...
Items per page:
1 - 5 of 5